HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer.

Abstract
The objective was to evaluate the relative efficacy of cryoablation (CRYO) versus external beam radiation (EBRT) for clinically locally advanced prostate cancer in a randomized clinical trial. Patients with histologically proven, clinically staged as T2C, T3A or T3B disease were randomized with 6 months of perioperative hormone therapy to one of the two procedures. Owing largely to a shift in practice to longer term adjuvant hormonal therapy and higher doses of radiation for T3 disease, only 64 out of the planned 150 patients were accrued. Twenty-one of 33 (64%) in the CRYO group and 14 of 31 (45%) in the EBRT-treated group who had met the ASTRO definition of failure were also classified as treatment failure. The mean biochemical disease-free survival (bDFS) was 41 months for the EBRT group compared to 28 months for the CRYO group. The 4-year bDFS for EBRT and CRYO groups were 47 and 13%, respectively. Disease-specific survival (DSS) and overall survival (OS) for both groups were very similar. Serious complications were uncommon in either group. EBRT patients exhibited gastrointestinal (GI) adverse effects more frequently. Taking into account the relative deficiency in numbers and the original trial design, this prospective randomized trial indicated that the results of CRYO were less favorable compared to those of EBRT, and was suboptimal primary therapy in locally advanced prostate cancer.
AuthorsJ L Chin, C-K Ng, N J Touma, N J Pus, R Hardie, M Abdelhady, G Rodrigues, J Radwan, V Venkatesan, M Moussa, D B Downey, G Bauman
JournalProstate cancer and prostatic diseases (Prostate Cancer Prostatic Dis) Vol. 11 Issue 1 Pg. 40-5 ( 2008) ISSN: 1476-5608 [Electronic] England
PMID17579613 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Hormonal
Topics
  • Aged
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Cryosurgery
  • Humans
  • Male
  • Neoplasm Recurrence, Local (diagnosis)
  • Neoplasm Staging
  • Prostatic Neoplasms (radiotherapy, surgery)
  • Radiotherapy, High-Energy
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: